U.S. pricing has been the bigegts issue of the year for drugmakers heavily exposed to the U.S. market.
This is how exposed European Big Pharma is to the U.S.
Related Posts
European markets open 1% higher as Nvidia results ease investor concerns over AI bubble
European stocks started the Thursday trading session higher, mirroring market moves in Asia.
European Central Bank to make ‘last easy rate cut’ as tariffs, higher fiscal spending loom
Disagreement among policymakers may be set to increase as the neutral rate swims into view.
AI wealth must benefit the public, South Korea’s deputy PM says amid Samsung labor tensions
South Korea’s deputy PM tells CNBC there are concerns as to whether AI could worsen wealth gaps or lead to…